Video Experimental Relacionado
Updated: Jul 16, 2026
07:45
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
La integrina beta 4 amplifica la señalización ErbB2 para promover la tumorigénesis mamaria
Wenjun Guo1, Yuliya Pylayeva, Angela Pepe
1Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 USA.
Cell
|August 12, 2006
Resumen
La integrina beta 4 amplifica la señalización de ErbB2, promoviendo el cáncer de mama agresivo. La señalización dirigida a la beta 4 suprime el crecimiento tumoral y mejora la eficacia de la terapia dirigida a ErbB2.
Área de la Ciencia:
- Oncología Oncología.
- Biología Molecular Biología Molecular
- Biología celular Biología celular.
Sus antecedentes:
- La amplificación del gen ErbB2 es frecuente en tumores mamarios agresivos, asociados con un mal pronóstico.
- Los mecanismos de la progresión del cáncer de mama impulsada por ErbB2 no se comprenden completamente.
- La integrina beta 4 es un receptor de adherencia celular y de señalización implicado en la tumorigénesis.
Objetivo del estudio:
- Para investigar el papel de la señalización de la integrina beta 4 en el cáncer de mama mediado por ErbB2.
- Para determinar si la integrina beta 4 contribuye al inicio del tumor, la invasión y la respuesta terapéutica.
Principales métodos:
- Utilizó un modelo de ratón de carcinoma mamario inducido por ErbB2.
- Se introdujo una supresión dirigida del dominio de señalización de la integrina beta 4.
- Se realizaron estudios ex vivo para analizar la formación de complejos proteicos y la activación del factor de transcripción.
Principales resultados:
- La pérdida de la señalización de la integrina beta 4 suprimió la aparición de tumores mamarios y el crecimiento invasivo.
- La integrina beta 4 forma un complejo con ErbB2, mejorando la activación de STAT3 y c-Jun.
- Se observaron alteraciones STAT3 de la adhesión/polaridad epitelial y hiperproliferación impulsada por c-Jun.
- La eliminación del dominio de señalización beta 4 mejoró la eficacia de la terapia dirigida a ErbB2.
Conclusiones:
- La integrina beta 4 promueve la progresión del cáncer de mama mediante la amplificación de las vías de señalización ErbB2.
- La integrina beta-4 se ha identificado como un objetivo terapéutico potencial para el cáncer de mama.
- La orientación a la beta 4 integrina puede mejorar las terapias dirigidas a ErbB2 existentes.
Videos de Conceptos Relacionados
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.